Company: RGNT
Filing Date: 2025-03-11
Form Type: F-1
Source: 0001213900-25-022350
Chunk: 288

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-03-11
Form: F-1
Chunk 288
---
 any such royalties to the IIA. As of December 31, 2023, total contingent obligation to IIA         
 is at the amount of $2,635 (including interest at the amount of $291).                                    |

| 2. | In February 2018, the Company                                                                                                     
 entered into a services agreement with Baxter Healthcare Corporation (the “Baxter Services Agreement” and “Baxter”,               
 respectively), pursuant to which the Company agreed to purchase certain services from the third party in connection with GelrinC. 
 In April 2022, we amended the Baxter Services Agreement to replace Teva Medical (Marketing) Ltd. (“Teva”) as the supplier         
 of Tisseel under the Supply Agreement for GelrinC with Baxter as Teva ceased to distribute Tisseel in the territory of Israel.    |

Under the Baxter Services Agreement,
Baxter provides the Company with quality, regulatory and technical support, for up to a maximum aggregate of 40 man-hours per year for
all such support. In consideration for receiving such support, the Company pays Baxter $60 per year until the Company will receive a
Food and Drug Administration (the “FDA”) approval to market GelrinC in the United States. Following FDA approval to market
GelrinC in the United States, the Company shall pay Baxter $200 per year during the term of this Services Agreement; however, the year
the Company will receive an FDA approval to market GelrinC in the United States, the Company must pay the remining $140 balance for that
year within 30 days after receiving such approval. The Company incurred expenses under the Services Agreement of $60 in each of the year
ended December 31, 2023 and 2022.

| 3. | In July 2008, the Company                                                                                                                 
 entered into a Supply Agreement with Baxter and Teva which was amended and restated on January 6, 2009, pursuant to which the Company     
 agreed to purchase Tisseel VHSD fibrin sealant Kit (the “Tisseel”), from Teva, with Teva being Baxter’s exclusive                         
 distribution agent in Israel for Tisseel, for manufacture of GelrinC. The Supply Agreement was amended and restated. The Supply Agreement 
 provides for up to 1,000 kits of Tisseel of the 2 ml Tisseel kit, or 500 kits of Tisseel of the 4 ml Tisseel kit, or 200 kits of